08.06.2018
![]()
DGAP-News: STADA Arzneimittel AG: Consent Solicitation for STADA Euro bond 2015/2022
DGAP-News: STADA Arzneimittel AG / Key word(s): Bond
STADA Arzneimittel AG: Consent Solicitation for STADA Euro bond 2015/2022
08.06.2018 / 15:00
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Bad Vilbel, June 8, 2018 - STADA Arzneimittel AG ("STADA") has today
published the solicitation to the noteholders of the STADA Euro bond
2015/2022 (ISIN: XS1213831362, WKN: A14KJP, Common Code: 121383136) (the
"STADA 2015 Notes"), to vote without a physical meeting with the object of
appointing a common representative and making related mechanical amendments
to the conditions of the STADA 2015 Notes (the "Consent Solicitation").
This modification to the STADA 2015 Notes is being arranged by STADA in
connection with the provision of credit support by STADA and certain of its
subsidiaries under the 2017 financing provided to its majority shareholder,
Nidda Healthcare GmbH (the "Security"). The appointment of the common
representative of the STADA 2015 Notes is designed to procure the extension
of the Security to the holders of the STADA 2015 Notes on an equal and
rateable basis with Nidda Healthcare GmbH's creditors under the 2017
financing. Accordingly, holders of the STADA 2015 Notes are encouraged to
attend the noteholder meeting set out in the Consent Solicitation.
STADA also intends to offer to acquire STADA 2015 Notes at par plus accrued
interest (to the date of acquisition) giving those holders who do not wish
to participate in the proposed consents the ability to sell their STADA 2015
Notes. Details and conditions of the related tender offer for cash will be
announced separately and nearer the time for the vote in respect of the
Consent Solicitation.
Contact:
STADA Arzneimittel AG / Corporate Treasury / Frank Seiler / Stadastrasse
2-18 / 61118 Bad Vilbel - Germany / Tel.: +49 (0) 6101 603-4476 / Fax: +49
(0) 6101 603-3721 / E-mail: [email protected]
Or visit us on the Internet at www.stada.com
---------------------------------------------------------------------------
08.06.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: STADA Arzneimittel AG
Stadastraße 2-18
61118 Bad Vilbel
Germany
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: [email protected]
Internet: www.stada.de
ISIN: DE0007251803
WKN: 725180
Indices: SDAX
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime
Standard); Regulated Unofficial Market in Berlin, Hamburg,
Hanover, Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
693883 08.06.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
STADA Arzneimittel AG ISIN: DE0007251803 können Sie bei DGAP abrufen
Gesundheit , 725180 , SAZ , XETR:SAZ